Related Experiment Video
Updated: Aug 24, 2025
08:56
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
52.7K
Obeticholic Acid for Primary Biliary Cholangitis.
Annarosa Floreani1,2, Daniela Gabbia3, Sara De Martin3
1Department of Surgery, Oncology and Gastroenterology, University of Padova, 35131 Padova, Italy.
Biomedicines
|October 27, 2022
Summary
Primary biliary cholangitis (PBC) is an autoimmune liver disease. Obeticholic acid (OCA) offers a second-line treatment option for patients unresponsive to ursodeoxycholic acid (UDCA), showing promise in managing this rare condition.
Area of Science:
- Hepatology and autoimmune liver diseases.
- Pharmacology and drug development for cholestatic conditions.
Background:
- Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by progressive fibrosis and cirrhosis.
- Current treatment options for PBC are limited, with ursodeoxycholic acid (UDCA) as the standard first-line therapy.
- A significant proportion of patients (30-40%) exhibit an inadequate response to UDCA, necessitating alternative therapeutic strategies.
Purpose of the Study:
- To review the pharmacological characteristics of obeticholic acid (OCA).
- To evaluate the tolerability and efficacy of OCA in patients with PBC.
- To discuss emerging perspectives on future therapies for PBC.
Main Methods:
- Literature review focusing on pharmacological properties, clinical trials, and real-world data of OCA in PBC.
- Analysis of mechanism of action, including FXR agonism.
- Synthesis of data on efficacy endpoints (biochemical, histological) and safety profiles.
Main Results:
- Obeticholic acid (OCA) acts as a farnesyl X receptor (FXR) agonist, modulating bile acid synthesis and transport.
- Clinical studies demonstrate OCA's efficacy in improving liver biochemistry markers in UDCA-intolerant or non-responsive PBC patients.
- Tolerability data indicate that while generally well-tolerated, potential side effects require careful monitoring.
Conclusions:
- Obeticholic acid (OCA) represents a crucial second-line treatment option for primary biliary cholangitis (PBC) patients who do not respond adequately to ursodeoxycholic acid (UDCA).
- Understanding OCA's pharmacology and clinical profile is essential for optimizing its use in managing PBC.
- Continued research into novel therapeutic agents is vital to address the unmet needs in PBC treatment.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
223
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
223
01:17Chronic Bowel Disorders: Introduction
525
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
525
01:29Inflammatory Bowel Disease IV: Pharmacological Management
172
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
172
01:21Drugs for Treatment of Constipation-Predominant IBS
293
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
293
01:24Chronic Pancreatitis I: Introduction
135
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
135
01:29Chronic Pancreatitis II: Collaborative Care
123
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
123